Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear.
Avastin® (bevacizumab) is a protein drug widely used for cancer treatment although its further use is questionable due to serious side effects reported. As no systematic proteomic study on posttranslational modifications (PTMs) was reported so far, it was the aim of the current study to use a gel-ba...
Main Authors: | Jia Wan, Edina Csaszar, Wei-Qiang Chen, Kongzhao Li, Gert Lubec |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22523550/?tool=EBI |
Similar Items
-
Using intravitreal bevacizumab (Avastin®) – Indian Scenario
by: Atul Kumar, et al.
Published: (2017-01-01) -
Intravitreal Bevacizumab (Avastin) Injection for Neovascular Glaucoma
by: Shahin Yazdani, et al.
Published: (2008-12-01) -
Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma
by: Subrata Mandal, et al.
Published: (2011-01-01) -
Management of Primary Pterygium with Intralesional Bevacizumab (AVASTIN) Injection
by: Irum Mahmood, et al.
Published: (2023-02-01) -
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
by: Sinapis C, et al.
Published: (2011-05-01)